TxCell gains Treg rights

Inserm Transfert is acting on behalf of Inserm, the Nantes University (Nantes, France) and the Nantes CHU. It has granted TxCell the exclusive worldwide license to two patent families filed by the Center for Research in Transplantation and Immunology (CRTI), a center of excellence in the field of transplantation and immunology.

These patents cover CD8+ Tregs, a new type of regulatory T cells (Tregs) that express the CD8 marker rather than CD4 like previously discovered Tregs. 

These CD8+ Tregs are non-cytotoxic and display a unique and highly immunosuppressive mechanism of action. Therefore, they may offer a effective treatment for inflammatory disorders, among them autoimmunity and transplant rejection. 

The CRTI team already demonstrated the efficacy of these CD8+ Treg cell population in several preclinical models of inflammation including heart allograft, human skin transplant rejection and graft-versus-host disease in mice with humanised immune systems. In these models, the administration of CD8+ Treg cells has been shown to prevent the occurrence of skin graft rejection and GvHD, respectively. With the current agreement, TxCell gains exclusive worldwide rights to both these patent families for all autoimmune diseases and transplantation-related disorders. 

"Regulatory T cells are composed of several subpopulations that act through complementary modes of action to prevent or treat inflammatory disorders. TxCell’s unparalleled patent estate is focused on therapeutic Treg cells and already covers type 1 Treg cells and CAR-Treg cells. TxCell, by obtaining an exclusive license on patents covering a new CD8+ Treg cell subpopulation, adds a new pillar to its patent portfolio and further strengthens TxCell’s position as the international Treg leading expert," said Arnaud Foussat, Senior Vice President, Corporate Development and Head of External Collaborations & Alliance Management of TxCell. "This is the fifth academic agreement signed in 2016. Specifically, this license enables TxCell to develop new types of cell therapy products, composed of CD8+ Treg cells, including CAR‑CD8+ Tregs, for the treatment of autoimmune diseases as well as transplant-related disorders with high unmet medical need."

"It is a great satisfaction for Inserm Transfert to be involved in such a major technology transfer and to complete it successfully. This license agreement is the first step towards future collaborations with TxCell," said Pascale Augé, President of Board of Inserm Transfert.